Vera J. Suman

Serum sErbB1 and epidermal growth factor levels as tumor biomarkers in women with stage III or IV epithelial ovarian cancer.

V. Suman, K. Podratz, A. Baron, 1999, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

Functional genetic polymorphisms in the aromatase gene CYP19 vary the response of breast cancer patients to neoadjuvant therapy with aromatase inhibitors.

B. Fridley, G. Jenkins, R. Weinshilboum, 2010, Cancer research.

Functional Annotation of ESR1 Gene Fusions in Estrogen Receptor-Positive Breast Cancer

Sherri, R. Matsunuma, D. Chan, 2018, Cell reports.

Evaluation of tamoxifen plus letrozole with assessment of pharmacokinetic interaction in postmenopausal women with metastatic breast cancer.

E. Perez, M. Dowsett, J. Ingle, 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

Endocrine-Sensitive Disease Rate in Postmenopausal Patients With Estrogen Receptor–Rich/ERBB2-Negative Breast Cancer Receiving Neoadjuvant Anastrozole, Fulvestrant, or Their Combination

C. Perou, J. Hoog, M. Anurag, 2024, JAMA oncology.

ACOSOG Z1031: A randomized phase II trial comparing exemestane, letrozole, and anastrozole in postmenopausal women with clinical stage II/III estrogen receptor-positive breast cancer.

J. Olson, G. Babiera, K. Hunt, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.